Gene therapy for inherited retinal diseases—rare genetic conditions that cause progressive vision loss—remains largely stuck in the pipeline, with only one FDA-approved treatment available nine years after the first breakthrough. While the field has exploded with new research and clinical trials, experts say the real challenge isn't the science—it's figuring out how to measure success in ways that satisfy regulators and actually help patients avoid blindness. What Are Inherited Retinal Diseases? Inherited retinal diseases (IRDs) are a group of genetic disorders that damage the light-sensing cells in the retina, the tissue at the back of the eye that captures images and sends them to the brain. These conditions are incredibly diverse—scientists have identified an average of nine new disease-causing genes annually since 1990, making IRDs the most genetically heterogeneous group of disorders in humans. Some forms appear at birth or in early childhood, while others develop later in life, gradually stealing vision over time. The impact is significant: IRDs are a leading cause of inherited blindness, affecting thousands of people worldwide. Yet until recently, treatment options barely existed. One Approval in Nine Years: Where's the Progress? In 2017, the FDA approved voretigene neparvovec-rzyl (Luxturna), a gene therapy developed by Spark Therapeutics for patients with Leber congenital amaurosis type 2 or severe early-onset retinitis pigmentosa. This was a watershed moment—the first FDA-approved gene therapy in all of medicine, not just for eye disease. It proved that replacing a faulty gene could restore vision in real patients. But here's the problem: it's now 2026, and no other retinal gene therapy has reached FDA approval. "It's been nine years," explains Dr. Christine Kay, a vitreoretinal surgeon and inherited retinal disease specialist in Gainesville, Florida. "I used to say we had our first FDA approval a few years ago, and the next one soon to come, and now it's been nine years." The delay isn't because researchers have stopped trying. In fact, the opposite is true. "Probably every week, I have a company calling me about a new trial," says Dr. Mark Pennesi, chief medical officer and director of the Inherited Retinal Degeneration Center at the Retina Foundation of Dallas. The landscape has transformed dramatically from when he started practicing 16 years ago, when there were maybe one or two trials and they weren't very promising. Why Are Promising Trials Failing? The bottleneck isn't innovation—it's measurement. Several high-profile trials have failed not because the gene therapy didn't work, but because researchers and the FDA couldn't agree on how to measure success. "We've learned, painfully throughout the field in the last nine years, what our limitations are," Dr. Kay explains. "One thing we've learned is that outcome measures for inherited retinal diseases are quite limited." A striking example is achromatopsia, a rare condition where people are born colorblind and have severe light sensitivity. A clinical trial tested a gene therapy that should theoretically work perfectly—the disease involves cone dysfunction, the retina's structure is intact, and gene therapy is designed to replace faulty genes. Yet the trial failed to meet its endpoints. "It's sad to this day that we didn't get an FDA approval for a gene therapy for achromatopsia," Dr. Kay says. "Gene therapy for this disease should work. If we have the right vector and the right endpoint, it should absolutely work." The Real Problem: Measuring Success in Slow-Moving Diseases Inherited retinal diseases progress slowly—sometimes over decades. This creates a measurement challenge that most clinical trials aren't designed to handle. Researchers may choose endpoints (the outcomes they're measuring) that are too strict, too difficult to achieve, or simply the wrong metric for the disease. "Several trials that haven't succeeded in the last few years failed because the endpoint was either too difficult, the threshold too high, or the wrong endpoint was chosen because of a lack of understanding of natural history," Dr. Kay explains. Many current outcome measures were borrowed from glaucoma research and don't fit retinal diseases well. For instance, traditional perimetry (visual field testing) uses five points and seven decibels—metrics that made sense for glaucoma but may not capture meaningful vision improvement in retinal disease patients. How Experts Are Working to Fix the System - Better Natural History Studies: Researchers need to understand how each disease progresses naturally over time, so they can choose realistic and meaningful endpoints that actually reflect patient benefit. - New Measurement Tools: Advanced testing methods like full-field stimulus testing, microperimetry, maze-based mobility testing, and optical coherence tomography (OCT)-based structure-function correlations are now trusted by regulators and make trials more robust. - FDA Communication: Retina specialists are working with organizations like the Foundation Fighting Blindness to form clinical trial summit endpoints groups aimed at helping the FDA understand which outcome measures should be considered approvable for retinal diseases. - Smarter Trial Design: Broader access to genetic testing and clearer understanding of how genes map to disease symptoms is allowing researchers to design more targeted trials with better endpoints from the start. What This Means for Patients Right Now The good news is that hope within the field is palpable. Therapies are moving closer to potential approval, and the scientific foundation is stronger than ever. Advancements in genetics, technology, engineering, and outcome measurements have all contributed to better understanding of disease and therefore better treatment. Dr. Brittni Scruggs, an adult and pediatric vitreoretinal surgeon at the Mayo Clinic, notes that "Luxturna, the first FDA-approved gene therapy in all of medicine, established this model and demonstrated that gene therapy could be translated into real-world clinical medicine". But patients with inherited retinal diseases shouldn't wait passively. If you or a family member has been diagnosed with an IRD, staying connected with specialists and asking about clinical trials is crucial. The field is moving faster than ever—it just needs to align on how to prove it works.
